Phase II Study of the Modified Regimen of Etoposide, Leucovorin and 5-Fluorouracil for Patients with Advanced Gastric Cancer

Japanese Journal of Clinical Oncology

Volumn 28, Issue 5, 1998, Pages 318-322

  Chiou, Tzeon Jye ^a,b   Tung, Shiao Lin ^a   Hsieh, Ruey Kuen ^a   Wang, Wei Shu ^a   Yen, Chueh Chuan ^a   Fan, Frank S ^a   Liu, Jin Hwang ^a   Chen, Po Min ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Advanced gastric cancer; Modified ELF; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ELF PROTOCOL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DIARRHEA; DRUG ADMINISTRATION; FEMALE; HUMAN; LEUKOPENIA; MALE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; STOMACH TUMOR; SURVIVAL;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOPENIA; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0032059909     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.5.318     Document Type: Article

References (23)

1. Silverberg E, Boring CC, Squires TS. Cancer statistics. CA 1990;40:9-26.
2. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer 1991;67(Suppl 1):260-5.
3. Comis RL, Carter SK. A review of chemotherapy in gastric cancer. Cancer 1974;34:1576-86.
4. Norum J, Angelsen V. Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens. J Chemother 1995;7:455-9.
5. Macdonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, et al. 5-Fluorouiacil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-6.
6. Wils J. The treatment of advanced gastric cancer. Semin Oncol 4 1996;23:397-406.
7. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17(Suppl 2):61-70
8. Wilke H, Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer-a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 1990;8:65-70
9. di Bartolomeo M, Bajetta E, de Brand F, Bochicchio AM, Gebbia V, Bozzetti F, et al. Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology 1995;52:41-4
10. Van Custem E, Fielz L, Dewyspelaere J, Penninckx F, Janssens J. Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study. Anticancer Res 1995;15:1079-80.
11. Chiou TJ, Chen PM, Lei YY. Chemotherapy of advanced gastric cancer with ELF-A preliminary report. J Chin Oncol Soc 1992;8:103 (Abstr).
12. Miller AB, Hoogstraten B, Staquet M, Winkler A Reporting results of cancer treatment. Cancer 1981;47:207-14
13. Kaplan HS, Meir P. Nonparametric estimation from incomplete observations. Am Statist Assoc 1958;53:457-81.
14. Taal BG, Teller FG, ten Bokkel Huinink WW, Boot H, Beijinen JH, Dubbelman R. Etoposide, leucovorin. 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 1994;5 90-2.
15. Van Cutsem E, Filez L, Janssens J, Penninckx F, Kerremans R, Vantrappen G. Phase II study of etoposide. leucovorin and 5-fluorouracil (5-Fu) in advanced gastric cancer. Anticancer Res 1992;12:1793-4.
16. Spiers A, Sanderson R, Huffman M, Williams C. Ineffectiveness of high-dose 5-fluororacil (5-Fu) in previously colorectal cancer and other solid tumors. Proc Am Soc Clin Oncol 1991;10:A445
17. Geffen JR, Venook AP, Luce J, Jensen B, Glassberg A, Newman A, et al. Phase II trial of VP-16, leucovorin and fluorouracil (ELF) in advanced gastric carcinoma. Proc Am Soc Clin Oncol 1992;11:A595.
18. Preusser P, Iike H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer J Clin Oncol 1989;7:1310-17.
19. Lerner A, Gonin R, Steele GD Jr, Mayer RJ. Etoposide, doxorubicin and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 1992;10:536-40.
20. Wils JA, Klein HO, Wagener DJTh, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.
21. Kelson D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, et al. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-8.
22. The Gastrointestinal Tumor Study Group. A combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 1982;49:1771-7.
23. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 1989;7:1318-26.